Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes

Published:2015-09-04 Issue:11 Volume:17 Page:1075-1084
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Matthaei S.¹,Bowering K.²,Rohwedder K.³,Sugg J.⁴,Parikh S.⁵,Johnsson E.⁶,

Affiliation:

1. Diabetes-Zentrum Quakenbrück; Quakenbrück Germany

2. University of Alberta; Department of Medicine; Alberta Canada

3. AstraZeneca; Wedel Germany

4. Formerly AstraZeneca; Wilmington DE USA

5. AstraZeneca; Gaithersburg MD USA

6. AstraZeneca; Mölndal Sweden

Funder

AstraZeneca

Bristol-Myers Squibb

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12543/fullpdf

Reference30 articles.

1. Metformin-the gold standard in type 2 diabetes: what does the evidence tell us?;Bosi;Diabetes Obes Metab,2009

2. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride;Korytkowski;Pharmacotherapy,2004

3. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?;Leibowitz;Diabetologia,1996

4. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes;Hermann;Diabetes Obes Metab,2002

5. Standards of medical care in diabetes-2015: summary of revisions;Diabetes Care,2015

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of Dapagliflozin Dosing on Low‐Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus: A Systematic Literature Review and Meta‐Analysis;The Journal of Clinical Pharmacology;2024-08

2. Effects of dapagliflozin on body weight in patients with type 2 diabetes mellitus: Evidence‑based practice;Experimental and Therapeutic Medicine;2024-02-28

3. Metabolic and renal outcomes of empagliflozin in patients with type 2 diabetes mellitus attending Armed Forces Hospital in Saudi Arabia;Saudi Medical Journal;2023-07

4. Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Clinical Drug Investigation;2023-04

5. Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis;World Journal of Cardiology;2022-11-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3